The state’s largest medical cannabis company releases first-ever pharmaceutical grade products

(Albuquerque) – Ultra Health, New Mexico’s #1 medical cannabis company with a nationwide presence, has released the first pharmaceutical grade, accurately dosed medical cannabis products to the New Mexico market. The products provide reliable and easy-to-administer dosages of medical cannabis, which has been effective in treating a variety of ailments ranging from PTSD to cancer to chronic pain to epilepsy to Parkinson’s disease, among others.

The new products, developed with proprietary knowledge from Israeli pharmaceutical group Panaxia, include oils, tablets, sublingual tablets, rectal and vaginal suppositories, pastilles, patches, minor burn topicals, facial topicals and massage creams. They range from 10 to 200 milligrams of tetrahydrocannabinol (THC) and 5 to 300 milligrams of cannabidiol (CBD). The revolutionary medical cannabis products are not only discreet, but they provide previously unavailable delivery methods for medical cannabis patients.

The sublingual tablet delivers fast-acting relief to patients who have difficulty swallowing. The cheek area has many tiny blood vessels, which allow for the medication to be absorbed directly into the bloodstream without going into the digestive system, where the effects of the medication could potentially be decreased.

The rectal and vaginal suppositories are also fast-acting medications beneficial for patients suffering from nausea or having difficulty swallowing. The medications are inserted into the rectum or vagina with a special applicator. The body absorbs drugs faster than medications taken by mouth because suppositories melt inside the body and absorb directly into the bloodstream.

“Our main goal as a medical cannabis company is to give the patients the opportunity to purchase safe, affordable and convenient medicine,” said Duke Rodriguez, CEO and President of Ultra Health®. “There is no question that these products are meeting our clinical goals. We continue to reach our service goals with the opening of new stores in under-served, rural markets.”

“We believe that cannabis pharma grade products should be available to patients in order to fully explore the medicinal properties of this plant,” said Dr. Dadi Segal, CEO of Panaxia. “As with any type of medicine, our patients can expect precise dosage, good manufacturing practices (GMP) and clinical knowledge. Our company believes that in order to fully serve patients, the products we manufacture must be whole plant products and not synthetic or semi-synthetic cannabinoids.”

Ultra Health opened its manufacturing lab in March, which implements Panaxia’s technology, including advanced GMP production protocols as well as validated analytical system and proprietary production technology. Panaxia is providing Ultra Health exclusive rights to its smokeless proprietary cannabinoid dosage and treatment protocols, which have been available in the United States.

About Ultra Health

Ultra Health is a turnkey solutions provider for the specialty healthcare cannabis industry, with operations and facilities in Arizona and New Mexico. From retail dispensaries to commercial-scale cannabis production, Ultra Health offers the unmatched technical expertise, proprietary business tools and deep industry knowledge to fulfill the specific requirements of any project related to the cannabis industry. Ultra Health partners with a broad spectrum of businesses and Tribal Nations to design, formulate and manage cannabis-related economic development opportunities that are profitable, scalable and mutually beneficial.

About Panaxia Pharmaceutical Industries Ltd

Panaxia Pharmaceutical Industries is a manufacturer of pharmaceutical dosage forms based in cannabis. The company is part of a larger group of companies, which have manufactured pharmaceuticals for more than 40 years. Altogether, the group produces more than 300 different conventional medication products, with a wide range of indications from sore throat lozenges to dermal fillers. The group sells in more than 25 countries and is R&D oriented. Panaxia pharmaceutical Industries has been developing and manufacturing pharmaceutical products based in cannabis since 2010.

 

###